Replies to post #234806 on Biotech Values

[bladerunner1717]

I think MYOV still gets approved. Less cardiac events.

Bladerunner

[semi_infinite]

MYOV - IYO is the market 1/3 discount since secondary endpoint implying clearance or drug pricing issue? Had a nibble and tempted to add.

[semi_infinite]

MYOV - back to where it was before secondary endpoint news. Looks like it will challenge 52 wk high before PDUFA.